Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer
Lumos Pharma
Lumos Pharma
Novartis
H. Lee Moffitt Cancer Center and Research Institute
Incyte Corporation
City of Hope Medical Center
Ipsen
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Hoffmann-La Roche
AstraZeneca
Novartis
Merck Sharp & Dohme LLC
UNC Lineberger Comprehensive Cancer Center
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC
AstraZeneca
Dana-Farber Cancer Institute
Emory University
SWOG Cancer Research Network
Hoffmann-La Roche
Emory University
Hoffmann-La Roche
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Gilead Sciences
Bristol-Myers Squibb
Bristol-Myers Squibb
Corcept Therapeutics
Daiichi Sankyo
Merck Sharp & Dohme LLC
Emory University
University of Iowa
Trishula Therapeutics, Inc.
City of Hope Medical Center
University of Chicago
City of Hope Medical Center
ImmunoGenesis
Precision Biologics, Inc
University of Chicago
Pancreatic Cancer Action Network
Amgen
EpicentRx, Inc.
Washington University School of Medicine
NYU Langone Health
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Washington University School of Medicine
ImmunityBio, Inc.
ImmunityBio, Inc.
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Immodulon Therapeutics Ltd